Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.
November 23 2021 - 8:12AM
InvestorsHub NewsWire
Pasithea
Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in
the U.K.
– Pasithea Clinics is one of only three accredited clinics in
the U.K. approved to offer esketamine nasal spray (SPRAVATO®) for
treatment of mental health disorders –
Miami Beach, FL -- November 23, 2021 -- InvestorsHub NewsWire
-- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a novel
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders, today announced that its wholly owned subsidiary,
Pasithea Clinics, has been approved to provide esketamine nasal
spray (SPRAVATO®) for treatment-resistant depression in adults, and
has begun offering the treatment in its Knightsbridge, London
location. Only three clinics in the U.K. have been accredited to
offer this treatment.
"This is an important milestone for our U.K. clinics and
their patients," stated Dr. Tiago Reis Marques, CEO of Pasithea
Therapeutics. "Major Depression is the leading cause of long-term
disability worldwide. Current treatments have limited success and
up to 30% of patients with depression do not respond to consecutive
trials of antidepressant treatment. These patients are considered
to have treatment-resistant depression
and new treatment options are urgently
needed."
"Esketamine is safe and effective, especially when combined
with ongoing psychiatric support. Due to some risks associated with
this drug, patients treated in outpatient settings must be enrolled
in a specific program. We are extremely proud to have been
accredited to provide this treatment, a reflection of our high
standards of care," said Dr. Yassine Bendiabdallah, Managing
Director of Pasithea Clinics in the U.K.
About SPRAVATO®
SPRAVATO® (esketamine) CIII nasal spray is a non-selective,
non-competitive antagonist of the N-methyl-D-aspartate (NMDA)
receptor – an ionotropic glutamate receptor. It has a novel
mechanism of action, meaning it works differently than currently
available therapies for major depressive disorder (MDD).
SPRAVATO® is approved in the United States, in conjunction
with an oral antidepressant, to treat adults with
treatment-resistant depression (TRD) and depressive symptoms in
adults with MDD with acute suicidal ideation or behavior. SPRAVATO®
has been submitted for health authorities' review for TRD and
adults with MDD who have current suicidal ideation with intent in
other markets around the world, including Europe.
About Pasithea
Therapeutics Corp.
Pasithea Therapeutics Corporation is a U.S. biotechnology
company focused on the research and discovery of new and effective
treatments for psychiatric and neurological disorders. With an
experienced team of experts in the fields of neuroscience and
psychopharmacology, Pasithea is developing new molecular entities
for the treatment of psychiatric and neurological disorders.
Pasithea is also focused on addressing the needs of patients
currently suffering with mental illness by providing access to IV
ketamine infusions both in clinics and in-home settings.
Forward
Looking Statements
This press release contains statements that constitute
"forward-looking statements." Forward-looking statements are
subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company's filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company
Contact
Dr. Tiago Reis
Marques
Chief Executive
Officer
E: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
Relations
Lisa M.
Wilson
In-Site
Communications, Inc.
T:
212-452-2793
E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Apr 2023 to Apr 2024